Stay updated with breaking news from Thomas Theuringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.GERMANTOWN, Md. & HILDEN, Germany ...
QIAGEN N.V.: QIAGEN Announces 20-F Annual Report Filing for 2020 Results QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website at https://corporate.qiagen.com/investor-relations/financial-reports About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable c...
QIAGEN and INOVIO Pharmaceuticals: QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's VGX-3100 for Advanced Cervical Dysplasia QIAGEN's bioinformatic expertise raises predictive biomarker power in INOVIO's patient selection First-in-class next generation sequencing (NGS) assay designed for use on Illumina NextSeq 550Dx QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-bas...
(2) QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 minutes. This comes after QIAGEN decided to proactively withdraw the first submission made in November 2020 for this product to address a chemistry-related issue. QIAGEN believes it has resolved the issue, and data is now being collected for submission to the FDA. The eHub used to read ou...
QIAGEN N.V.: QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAGEN started cross-checking variants in May 2020 and continues to conduct biweekly assessments QIAseq SARS-CoV-2 Primer Panel helps with sequencing RNA and identifying mutations QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral varian...